24 related articles for article (PubMed ID: 34727304)
21. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.
Ma R; Xu L; Qu X; Che X; Zhang Y; Fan Y; Li C; Guo T; Hou K; Hu X; Drew L; Shen M; Cheung T; Liu Y
Br J Cancer; 2018 May; 118(11):1453-1463. PubMed ID: 29755114
[TBL] [Abstract][Full Text] [Related]
22. Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.
Yao H; Sun Q; Zhu J
Arch Pharm (Weinheim); 2016 Oct; 349(10):808-815. PubMed ID: 27624806
[TBL] [Abstract][Full Text] [Related]
23. Active Ras induces heterodimerization of cRaf and BRaf.
Weber CK; Slupsky JR; Kalmes HA; Rapp UR
Cancer Res; 2001 May; 61(9):3595-8. PubMed ID: 11325826
[TBL] [Abstract][Full Text] [Related]
24. High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma.
Al Shahrani M; Abohassan M; Y Alshahrani M; Hakami AR; Rajagopalan P
J Comput Aided Mol Des; 2021 Dec; 35(12):1165-1176. PubMed ID: 34727304
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]